<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124211">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692873</url>
  </required_header>
  <id_info>
    <org_study_id>PACAomics / IPC 2011-004</org_study_id>
    <nct_id>NCT01692873</nct_id>
  </id_info>
  <brief_title>Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors</brief_title>
  <acronym>PACAomics</acronym>
  <official_title>Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.

      Most patients present at diagnosis a non resectable, locally advanced or metastatic disease,
      with a median survival of 12 month.

      The aim of this study is the identification of diagnosis biomarkers, predictive of the
      therapeutic response.

      This project investigate the use of molecular analyses applied to pancreatic tumor cells
      collected by microbiopsy under ultrasound-endoscopy, and blood cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>within twenty four hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>within twenty four hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the histologic characteristics of the pancreatic tumor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pancreatic Tumor</condition>
  <arm_group>
    <arm_group_label>suspected pancreatic tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Realization of pancreatic tumor biopsy and blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>suspected pancreatic tumor</intervention_name>
    <description>Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.</description>
    <arm_group_label>suspected pancreatic tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspicion of pancreatic adenocarcinoma

          -  Patient &gt; 18 years old

          -  Social Security affiliation

          -  Signed informed consent

        Exclusion Criteria:

          -  Patient in emergency situation

          -  Major person being the object of a legal protective measure or unable to express its
             consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marine GILABERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>33 (0)4 91 22 37 78</phone>
    <email>bec@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnès BOYER CHAMMARD, MD</last_name>
    <phone>33 (0)4 91 22 37 78</phone>
    <email>bec@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marine GILABERT, MD</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr/</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 6, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic tumor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
